
    
      An open label 1:1 randomized phase II exploratory study investigating use of ctDNA-guided
      adjuvant chemotherapy compared to standard of care (SOC) after local treatment for metastatic
      colorectal cancer.

      Patients are randomized 1:1 between SOC and ctDNA guided treatment and follow-up.

      Escalation therapy comprises standard regimen of Fluorouracil (5-FU), Irinotecan and
      oxaliplatin (FOLFOXIRI), de-escalation therapy of monotherapy capecitabine or observation
      only. SOC is per institutional practice, based on national guidelines.
    
  